Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
7.11
Nov 13 • 3:59 PM ET Dollar change0.00 Percentage change(0.00%)
Aftermarket Close
7.11
Aftermarket • 4:15 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUT
Market Cap
739.97M
Enterprise Value
458.91M
Income
-136.95M
Sales
0.00M
Book/sh
2.77
Cash/sh
2.86
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
113
IPO
Oct 29, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
2.57
P/C
2.49
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
14.21
Current Ratio
14.21
Debt/Eq
0.06
LT Debt/Eq
0.04
Option/Short
Yes / Yes
EPS (ttm)
-1.67
EPS next Y
-1.25
EPS next Q
-0.30
EPS this Y
14.09%
EPS next Y
17.33%
EPS next 5Y
14.24%
EPS past 3/5Y
3.57% -11.28%
Sales past 3/5Y
- -
EPS Y/Y TTM
13.33%
Sales Y/Y TTM
-
EPS Q/Q
27.15%
Sales Q/Q
-
Insider Own
59.80%
Insider Trans
-0.02%
Inst Own
66.11%
Inst Trans
32.80%
ROA
-53.53%
ROE
-61.67%
ROIC
-45.61%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
7.45%
SMA50
8.67%
SMA200
4.71%
Trades
Shs Outstand
103.95M
Shs Float
41.84M
52W High
9.53 -25.43%
52W Low
4.73 50.32%
Volatility
8.21% 5.79%
ATR (14)
0.40
RSI (14)
57.29
Beta
0.43
Rel Volume
0.68
Avg Volume
903.57K
Volume
610,320
Perf Week
8.38%
Perf Month
12.15%
Perf Quarter
-7.42%
Perf Half Y
-8.14%
Perf YTD
30.46%
Perf Year
28.57%
Perf 3Y
-8.26%
Perf 5Y
-59.35%
Perf 10Y
-
Prev Close
7.11
Price
7.11
Change %
0.00%
Consensus
Strong Buy
Avg. Price Target
$16.60
Implied Upside
+133.5%
Analysts5incl. previous ratings
Rating Distribution5 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Nov 26, 2025Resumed
EVR logoEEvercore ISI
Outperform$13+82.8%
May 28, 2025Resumed
HH.C. Wainwright
Buy$22+209.4%
Jul 25, 2024Initiated
HH.C. Wainwright
Buy$21+195.4%
Jul 27, 2023Initiated
BNS logoBScotiabank
Sector Outperform
Apr 17, 2023Resumed
BBTIG Research
Buy$38+434.5%
Jul 19, 2022Initiated
JJMP Securities
Mkt Outperform$26+265.7%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gibney AnthonyOfficerJun 16 '26Proposed Sale6.4212,82482,330Jun 16 04:30 PM
Gibney Anthony SSee RemarksJun 16 '26Sale6.4212,82482,330265,354Jun 16 04:30 PM
Matrix Capital Management Comp10% OwnerMay 07 '26Sale5.646,922,87039,044,9870May 11 04:16 PM
Kilroy ConorOfficerApr 16 '26Proposed Sale7.0211,73882,402Apr 16 06:50 PM
Kilroy ConorSee RemarksApr 16 '26Sale7.0211,73882,401217,835Apr 16 06:49 PM
Kilroy ConorOfficerFeb 17 '26Proposed Sale5.0512,07961,037Feb 17 07:51 PM
Plavsic MarkOfficerFeb 17 '26Proposed Sale5.0515,89080,271Feb 17 07:50 PM
Hopkins Janet JillOfficerFeb 17 '26Proposed Sale5.0620,401103,231Feb 17 07:50 PM
Elazzouzi AmyOfficerFeb 17 '26Proposed Sale5.068,54943,261Feb 17 07:50 PM
de los Pinos ElisabetOfficerFeb 17 '26Proposed Sale5.0647,648241,063Feb 17 07:49 PM
Kilroy ConorSee RemarksFeb 17 '26Sale5.0512,07960,999167,234Feb 17 07:48 PM
Plavsic MarkChief Technology OfficerFeb 17 '26Sale5.0515,89080,244181,397Feb 17 07:47 PM
Hopkins Janet JillChief Medical OfficerFeb 17 '26Sale5.0620,401103,229232,284Feb 17 07:47 PM
Elazzouzi AmySenior Vice President, FinanceFeb 17 '26Sale5.068,54943,25875,532Feb 17 07:47 PM
de los Pinos ElisabetSee RemarksFeb 17 '26Sale5.0647,648241,099409,815Feb 17 07:46 PM
Elazzouzi AmyOfficerJan 20 '26Proposed Sale4.861,5817,684Jan 20 06:42 PM
de los Pinos ElisabetOfficerJan 20 '26Proposed Sale4.8616,92882,234Jan 20 06:42 PM
Elazzouzi AmySenior Vice President, FinanceJan 20 '26Sale4.861,5817,68484,081Jan 20 06:41 PM
de los Pinos ElisabetSee RemarksJan 20 '26Sale4.8616,92882,270457,463Jan 20 06:41 PM
Hopkins Janet JillOfficerNov 17 '25Proposed Sale5.4217,10992,735Nov 17 05:57 PM
Hopkins Janet JillChief Medical OfficerNov 17 '25Sale5.4217,10992,731252,685Nov 17 05:56 PM
Aura Biosciences, Inc. is a clinical-stage oncology company, which engages in developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The firm's product candidate belzupacap sarotalocan (AU-011) is in Phase 2 development for the first line treatment of choroidal melanoma, a vision and life-threatening form of eye cancer where standard of care radioactive treatments leave patients with major vision loss and severe comorbidities. The was founded by Elisabet de los Pinos in 2007 and is headquartered in Boston, MA.
Chief Medical Officer & President of Research and DevelopmentDr. J. Jill Hopkins M.D.
PresidentMs. Natalie C. Holles
Senior Vice President of FinanceMs. Amy Elazzouzi
Chief Operating OfficerMs. Susan Abu-Absi Ph.D.
Head of Investor Relations & Corporate CommunicationsAlex Dasalla